Abstract
It has been over 25 years since the first diagnosis of what would be known as AIDS. Although great strides in anti-HIV therapeutics have been made, there is still a great need for antiretrovirals that are effective against drug-resistant HIV. Enfuvirtide (ENF) is the first of a new class of fusion inhibitors to be approved by the US Food and Drug Administration for use in combination with other antiretroviral agents among HIV-1 infected patients with previous treatment experience. The inclusion of enfuvirtide in an optimized antiretroviral background regimen for the treatment of HIV-1 infected (treatment-experienced) patients followed the success of two critical clinical trials (TORO: T20 vs Optimized Regimen Only I and II). Even though injection-site reactions persisted in these trials, improved virological and immunological responses were observed among patients. Challenges associated with ENF treatment include the high cost of the drug, injection-site reactions, determining the optimal time to initiate treatment, and the potential for the selection of drug resistant mutants and viral evolution. ENF is a promising novel treatment for HIV infected individuals whose choices for effective treatment are limited by previous treatment and resistance. Understanding the implications of viral fitness and evolution in the presence of ENF treatment is crucial in determining effective and safe treatment regimens, particularly among treatment-experienced patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 433-439 |
| Number of pages | 7 |
| Journal | Therapeutics and Clinical Risk Management |
| Volume | 4 |
| Issue number | 2 |
| State | Published - May 28 2008 |
| Externally published | Yes |
Fingerprint
Keywords
- Drug resistance
- Enfuvirtide
- Evolution
- gp41
- HIV
- Salvage therapy
ASJC Scopus subject areas
- Medicine(all)
- Safety Research
- Pharmacology, Toxicology and Pharmaceutics(all)
- Chemical Health and Safety
- Pharmacology (medical)
Cite this
Enfuvirtide antiretroviral therapy in HIV-1 infection. / Kitchen, Christina M.R.; Nuno, Miriam A; Kitchen, Scott G.; Krogstad, Paul.
In: Therapeutics and Clinical Risk Management, Vol. 4, No. 2, 28.05.2008, p. 433-439.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Enfuvirtide antiretroviral therapy in HIV-1 infection
AU - Kitchen, Christina M.R.
AU - Nuno, Miriam A
AU - Kitchen, Scott G.
AU - Krogstad, Paul
PY - 2008/5/28
Y1 - 2008/5/28
N2 - It has been over 25 years since the first diagnosis of what would be known as AIDS. Although great strides in anti-HIV therapeutics have been made, there is still a great need for antiretrovirals that are effective against drug-resistant HIV. Enfuvirtide (ENF) is the first of a new class of fusion inhibitors to be approved by the US Food and Drug Administration for use in combination with other antiretroviral agents among HIV-1 infected patients with previous treatment experience. The inclusion of enfuvirtide in an optimized antiretroviral background regimen for the treatment of HIV-1 infected (treatment-experienced) patients followed the success of two critical clinical trials (TORO: T20 vs Optimized Regimen Only I and II). Even though injection-site reactions persisted in these trials, improved virological and immunological responses were observed among patients. Challenges associated with ENF treatment include the high cost of the drug, injection-site reactions, determining the optimal time to initiate treatment, and the potential for the selection of drug resistant mutants and viral evolution. ENF is a promising novel treatment for HIV infected individuals whose choices for effective treatment are limited by previous treatment and resistance. Understanding the implications of viral fitness and evolution in the presence of ENF treatment is crucial in determining effective and safe treatment regimens, particularly among treatment-experienced patients.
AB - It has been over 25 years since the first diagnosis of what would be known as AIDS. Although great strides in anti-HIV therapeutics have been made, there is still a great need for antiretrovirals that are effective against drug-resistant HIV. Enfuvirtide (ENF) is the first of a new class of fusion inhibitors to be approved by the US Food and Drug Administration for use in combination with other antiretroviral agents among HIV-1 infected patients with previous treatment experience. The inclusion of enfuvirtide in an optimized antiretroviral background regimen for the treatment of HIV-1 infected (treatment-experienced) patients followed the success of two critical clinical trials (TORO: T20 vs Optimized Regimen Only I and II). Even though injection-site reactions persisted in these trials, improved virological and immunological responses were observed among patients. Challenges associated with ENF treatment include the high cost of the drug, injection-site reactions, determining the optimal time to initiate treatment, and the potential for the selection of drug resistant mutants and viral evolution. ENF is a promising novel treatment for HIV infected individuals whose choices for effective treatment are limited by previous treatment and resistance. Understanding the implications of viral fitness and evolution in the presence of ENF treatment is crucial in determining effective and safe treatment regimens, particularly among treatment-experienced patients.
KW - Drug resistance
KW - Enfuvirtide
KW - Evolution
KW - gp41
KW - HIV
KW - Salvage therapy
UR - http://www.scopus.com/inward/record.url?scp=44149117693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44149117693&partnerID=8YFLogxK
M3 - Review article
C2 - 18728846
AN - SCOPUS:44149117693
VL - 4
SP - 433
EP - 439
JO - Therapeutics and Clinical Risk Management
JF - Therapeutics and Clinical Risk Management
SN - 1176-6336
IS - 2
ER -